TTD | Drug: D0Z1OR

Drug General Information
Drug ID	D0Z1OR
Former ID	DIB007262
Drug Name	IPP-204106
Synonyms	NucAnt 6L; N-6-L; Nucleolin antagonist (cancer), ImmuPharma; Nucleolin antagonist (cancer), ImmuPharma/CNRS; Nucleolin antagonist (cancer), ImmuPharma/Centre National de la Recherche Scientifique
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1/2	[524099]
Company	Centre National de la Recherche Scientifique (CNRS)
Target and Pathway
Target(s)	Nucleophosmin	Target Info	Modulator
Target(s)	Nucleolin	Target Info	Modulator
NetPath Pathway	TCR Signaling Pathway
NetPath Pathway	IL2 Signaling Pathway
Pathway Interaction Database	Aurora B signaling
	Validated targets of C-MYC transcriptional activation
	HIF-1-alpha transcription factor network
	BARD1 signaling eventsaurora_b_pathway:Aurora B signaling
	Regulation of Telomerase
	Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
WikiPathways	Host Interactions of HIV factors
	Nucleosome assemblyWP2272:Pathogenic Escherichia coli infection
	miR-targeted genes in squamous cell - TarBase
	miR-targeted genes in muscle cell - TarBase
	miR-targeted genes in lymphocytes - TarBase
	miR-targeted genes in epithelium - TarBase
References
Ref 524099	ClinicalTrials.gov (NCT01711398) Dose-finding Adaptive Phase I/IIa Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IPP-204106N on Advanced Solid Tumors. U.S. National Institutes of Health.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Drug Information